glp-1 agonist benefits Agonists in Cardiovascular Diseases: Mechanisms, Clinical Evidence, and Emerging Therapies GLP 1s for Weight Loss
Description
The hazard ratios for the full follow-up period in these analyses was 1.37 (95% confidence interval 0.84 to 2.23), 1.04 (0.69 to 1.57), and 0.99 (0.67 to 1.46), respectively
[Google Scholar] 13.Pi-Sunyer X., Astrup A., Fujioka K., Greenway F., Halpern A., Krempf M., Lau D.C., le Roux C.W., Violante Ortiz R., Jensen C.B., et al
In May, VCU researchers published a study in JAMA Network Open that suggested breast cancer patients who used GLP-1s had better outcomes than those who didn't take the medications
You can see if you are eligible for a Trulicity Savings Card here
